摘要
目的:观察养肺益肾颗粒联合常规疗法治疗慢性阻塞性肺疾病(COPD)稳定期的临床疗效及对生活质量、免疫功能的影响。方法:选取60例稳定期COPD患者,按随机数字表法分为对照组及治疗组各30例。对照组按照相关指南给予常规治疗,治疗组在对照组基础上口服养肺益肾颗粒。2组均连续观察治疗12周。比较2组治疗前后中医证候评分、改良呼吸困难指数(mMRC)、COPD评估测试评分(CAT)、细胞因子[血清单核细胞趋化蛋白(MCP-1)、γ-干扰素(IFN-γ)、白细胞介素-4(IL-4)、白细胞介素-10(IL-10)]、用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、第1秒用力呼气容积与用力肺活量的比值(FEV_(1)/FVC)的变化,观察2组临床疗效。结果:治疗后,2组咳嗽、喘息、胸闷、气短、乏力、紫绀评分均较治疗前降低;治疗组咳嗽、胸闷评分均低于对照组,差异均有统计学意义(P<0.01)。治疗后,2组mMRC、CAT评分均较治疗前降低,治疗组上述2项评分均低于对照组,差异均有统计学意义(P<0.05)。治疗后,治疗组FVC、FEV_(1)水平均低于对照组,但差异无统计学意义(P>0.05);FEV_(1)/FVC水平高于对照组(P<0.05)。治疗后,2组MCP-1、IFN-γ水平均较治疗前下降,IL-4水平均较治疗前上升,差异均有统计学意义(P<0.05);治疗组MCP-1、IFN-γ水平均低于对照组,IL-10水平高于对照组,差异均有统计学意义(P<0.05)。治疗组总有效率为90.00%,对照组总有效率为66.67%,2组比较,差异有统计学意义(P<0.05)。结论:养肺益肾颗粒联合常规疗法能缓解COPD稳定期的临床症状,改善呼吸困难,延缓疾病进展。
Objective:To observe the clinical effect of Yangfei Yishen granules combined with routine therapy for chronic obstructive pulmonary disease(COPD)at stable stage and its effect on quality of life and immune function.Methods:A total of60 cases of patients with COPD at stable stage were selected and divided into the control group and the treatment group according to the random number table method,with 30 cases in each group.The control group was given routine treatment according to relevant guidelines,and the treatment group was additionally given the oral administration of Yangfei Yishen granules based on the treatment of the control group.Both groups were observed and treated for 12 weeks.Before and after treatment,the changes in Chinese medicine syndrome scores,modified Medical Research Council(mMRC),COPD Assessment Test(CAT),cytokines including monocyte chemoattractant protein(MCP-1),γ-interferon(IFN-γ),interleukin-4(IL-4)and interleukin-10(IL-10)in serum,forced vital capacity(FVC),the forced expiratory volume in one second(FEV_(1)) and the ratio of forced expiratory volume in one second to forced vital capacity(FEV_(1)/FVC)in the two groups were compared.The clinical effects in the two groups were observed.Results:After treatment,the scores of coughing,wheezing,chest oppression,shortness of breath,lack of strength and cyanosis in the two groups were decreased when compared with those before treatment;the scores of coughing and chest oppression in the treatment group were lower than those in the control group,differences being significant(P<0.01).After treatment,the scores of mMRC and CAT in the two groups were decreased when compared with those before treatment,and the above two scores in the treatment group were lower than those in the control group,differences being significant(P<0.05).After treatment,the levels of FVC and FEV_(1) in the treatment group were lower than those in the control group,but the difference were not statistically significant(P>0.05),and the level of FEV_(1)/FVC was higher(P<0.05).Aft
作者
李强
翟春苗
周佳
吴迦勒
王国栋
孙圣淇
LI Qiang;ZHAI Chunmiao;ZHOU Jia;WU Jiale;WANG Guodong;SUN Shengqi
出处
《新中医》
CAS
2022年第1期73-77,共5页
New Chinese Medicine
基金
浙江省中医药科技计划项目(2021ZB192)
杭州市科技发展计划项目(20150633B38)。
关键词
慢性阻塞性肺疾病
养肺益肾颗粒
免疫功能
证候评分
临床疗效
Chronic obstructive pulmonary disease
Yangfei Yishen granules
Immune function
Syndrome scores
Clinical effect
